A potential hidden source of hepatitis C infection among noninjecting drug users
- PMID: 14986874
- DOI: 10.1080/02791072.2003.10400492
A potential hidden source of hepatitis C infection among noninjecting drug users
Abstract
Hepatitis C virus (HCV) is a major cause of chronic liver disease in the United States and worldwide. It is primarily transmitted through blood-to-blood contact with an infected individual. HCV is hyperendemic among injection drug users (IDUs), who contract the virus through contaminated syringes and drug preparation equipment shared with other IDUs. The prevalence of HCV is also high, to a lesser degree, among noninjection drug users, many of whom report no identifiable HCV risk exposures. This article reviews the epidemiological and virological evidence bearing on a potential hidden source of HCV infection among noninjection drug users: namely, the oral or intranasal transmission of HCV through the sharing of noninjection drug-use implements such as pipes or straws. While there is some epidemiological evidence supporting both oral and intranasal HCV transmission, most studies are hampered by methodological limitations. Thus, there is a need for prospective studies designed specifically to examine these potential routes of transmission. Current biological evidence does not refute either oral or intranasal transmission as possible sources of HCV infection, although more research is needed in the areas of oronasal HCV pathogenesis and the detection of HCV RNA in the nasal mucosa of intranasal drug users.
Similar articles
-
High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack.Liver Int. 2008 Jul;28(6):781-6. doi: 10.1111/j.1478-3231.2008.01688.x. Liver Int. 2008. PMID: 18312289
-
Sharing of noninjection drug-use implements as a risk factor for hepatitis C.Subst Use Misuse. 2004 Jan;39(2):211-24. doi: 10.1081/ja-120028488. Subst Use Misuse. 2004. PMID: 15061559
-
Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy.Clin Infect Dis. 2003 Jul 1;37(1):33-40. doi: 10.1086/375566. Epub 2003 Jun 24. Clin Infect Dis. 2003. PMID: 12830406
-
Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S330-5. doi: 10.1086/427475. Clin Infect Dis. 2005. PMID: 15768343 Review.
-
Can hepatitis C virus infection be eradicated in people who inject drugs?Antiviral Res. 2014 Apr;104:62-72. doi: 10.1016/j.antiviral.2014.01.002. Epub 2014 Jan 24. Antiviral Res. 2014. PMID: 24468275 Review.
Cited by
-
Global Mortality Burden of Cirrhosis and Liver Cancer Attributable to Injection Drug Use, 1990-2016: An Age-Period-Cohort and Spatial Autocorrelation Analysis.Int J Environ Res Public Health. 2018 Jan 22;15(1):170. doi: 10.3390/ijerph15010170. Int J Environ Res Public Health. 2018. PMID: 29361804 Free PMC article.
-
Hepatitis C virus and neurological damage.World J Hepatol. 2016 Apr 28;8(12):545-56. doi: 10.4254/wjh.v8.i12.545. World J Hepatol. 2016. PMID: 27134702 Free PMC article. Review.
-
Physiologic oxygen responses to smoking opioids: an observational study using continuous pulse oximetry at overdose prevention services in British Columbia, Canada.Harm Reduct J. 2024 May 3;21(1):89. doi: 10.1186/s12954-024-01011-z. Harm Reduct J. 2024. PMID: 38702702 Free PMC article.
-
Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.Dig Dis Sci. 2011 Aug;56(8):2449-55. doi: 10.1007/s10620-011-1770-3. Epub 2011 Jun 25. Dig Dis Sci. 2011. PMID: 21706207
-
Crack use as a public health problem in Canada: call for an evaluation of 'safer crack use kits'.Can J Public Health. 2005 May-Jun;96(3):185-8. doi: 10.1007/BF03403687. Can J Public Health. 2005. PMID: 15913081 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical